Portfolio AOP Health Austria
A Product overview with focus on Rare Diseases.
AOP Health's focus is on integrated therapies for rare diseases and in critical care. The portfolio comprises products in the following therapeutic areas: Hemato-oncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Critical Care. AOP Health’s strategic goal is to constantly deliver new treatment options with respect to rare diseases and critical care.
Ambrisentan AOP is used to treat adult patients with pulmonary arterial hypertension (PAH) functional class II and III including combination therapy.
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia vera without symptomatic splenomegaly.
Canemes® can prevent nausea and vomiting in patients undergoing chemotherapy for malignant tumours and is used if other drugs do not have the desired effect.
Dependex® is indicated for pharmacological support in chronic alcohol withdrawal treatment
Empesin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.
Esmocard® is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
"Complete or partial reversal of CNS depressive effects, especially respiratory depression, caused by natural or synthetic opioids and partial agonist/antagonist opioids. It is also used to diagnose a suspected acute opioid overdose or intoxication or to reduce the effect of opioids, which were used for anesthesia in operations."
Ospolot® is an antiepileptic drug and is used to treat Rolandic epilepsy.
Adepend is used as part of a comprehensive treatment program against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Landiolol is not intended for use in chronic settings.
Tadalafil AOP is used to treat adults with pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity).
Tetmodis® is used as symptomatic therapy in the treatment of hyperkinetic motor disorders in Huntington’s disease. Tetrabenazine is also used in etiologies such as tardive dyskinesia, tics and dystonia.
Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients
Treatment of idiopathic or hereditary pulmonary arterial hypertension (PAH) for improving exercise capacity and alleviate disease symptoms in patients with New York Heart Association (NYHA) Functional Class III.